Simultaneous MV-kV imaging for intrafractional motion management during volumetric-modulated arc therapy delivery

Application of motion prediction based on a long short-term memory network for imaging dose reduction in real-time tumor-tracking radiation therapy

PURPOSE

To demonstrate the possibility of using a lower imaging rate while maintaining acceptable accuracy by applying motion prediction to minimize the imaging dose in real-time image-guided radiation therapy.

METHODS

Time-series of three-dimensional internal marker positions obtained from 98 patients in liver stereotactic body radiation therapy were used to train and test the long-short-term memory (LSTM) network. For real-time imaging, the root mean squared error (RMSE) of the prediction on three-dimensional marker position made by LSTM, the residual motion of the target under respiratory-gated irradiation, and irradiation efficiency were evaluated. In the evaluation of the residual motion, the system-specific latency was assumed to be 100 ms.

RESULTS

Except for outliers in the superior-inferior (SI) direction, the median/maximum values of the RMSE for imaging rates of 7.5, 5.0, and 2.5 frames per second (fps) were 0.8/1.3, 0.9/1.6, and 1.2/2.4 mm, respectively. The median/maximum residual motion in the SI direction at an imaging rate of 15.0 fps without prediction of the marker position, which is a typical clinical setting, was 2.3/3.6 mm. For rates of 7.5, 5.0, and 2.5 fps with prediction, the corresponding values were 2.0/2.6, 2.2/3.3, and 2.4/3.9 mm, respectively. There was no significant difference between the irradiation efficiency with and that without prediction of the marker position. The geometrical accuracy at lower frame rates with prediction applied was superior or comparable to that at 15 fps without prediction. In comparison with the current clinical setting for real-time image-guided radiation therapy, which uses an imaging rate of 15.0 fps without prediction, it may be possible to reduce the imaging dose by half or more.

CONCLUSIONS

Motion prediction can effectively lower the frame rate and minimize the imaging dose in real-time image-guided radiation therapy.

Real-time liver motion estimation via deep learning-based angle-agnostic X-ray imaging

BACKGROUND

Real-time liver imaging is challenged by the short imaging time (within hundreds of milliseconds) to meet the temporal constraint posted by rapid patient breathing, resulting in extreme under-sampling for desired 3D imaging. Deep learning (DL)-based real-time imaging/motion estimation techniques are emerging as promising solutions, which can use a single X-ray projection to estimate 3D moving liver volumes by solved deformable motion. However, such techniques were mostly developed for a specific, fixed X-ray projection angle, thereby impractical to verify and guide arc-based radiotherapy with continuous gantry rotation.

PURPOSE

To enable deformable motion estimation and 3D liver imaging from individual X-ray projections acquired at arbitrary X-ray scan angles, and to further improve the accuracy of single X-ray-driven motion estimation.

METHODS

We developed a DL-based method, X360, to estimate the deformable motion of the liver boundary using an X-ray projection acquired at an arbitrary gantry angle (angle-agnostic). X360 incorporated patient-specific prior information from planning 4D-CTs to address the under-sampling issue, and adopted a deformation-driven approach to deform a prior liver surface mesh to new meshes that reflect real-time motion. The liver mesh motion is solved via motion-related image features encoded in the arbitrary-angle X-ray projection, and through a sequential combination of rigid and deformable registration modules. To achieve the angle agnosticism, a geometry-informed X-ray feature pooling layer was developed to allow X360 to extract angle-dependent image features for motion estimation. As a liver boundary motion solver, X360 was also combined with priorly-developed, DL-based optical surface imaging and biomechanical modeling techniques for intra-liver motion estimation and tumor localization.

RESULTS

With geometry-aware feature pooling, X360 can solve the liver boundary motion from an arbitrary-angle X-ray projection. Evaluated on a set of 10 liver patient cases, the mean (± s.d.) 95-percentile Hausdorff distance between the solved liver boundary and the "ground-truth" decreased from 10.9 (±4.5) mm (before motion estimation) to 5.5 (±1.9) mm (X360). When X360 was further integrated with surface imaging and biomechanical modeling for liver tumor localization, the mean (± s.d.) center-of-mass localization error of the liver tumors decreased from 9.4 (± 5.1) mm to 2.2 (± 1.7) mm.

CONCLUSION

X360 can achieve fast and robust liver boundary motion estimation from arbitrary-angle X-ray projections for real-time imaging guidance. Serving as a surface motion solver, X360 can be integrated into a combined framework to achieve accurate, real-time, and marker-less liver tumor localization.

Clinical validation of the Varian Truebeam intra-fraction motion review (IMR) system for prostate treatment guidance

This study quantified the performance of Intra-fraction Motion Review (IMR) during prostate Stereotactic Body Radiotherapy (SBRT) treatments. IMR was evaluated using prostate motion data from patients treated in an SBRT clinical trial (PROMETHEUS, NCT00587990).IMR measured prostate displacements were compared to those of two 3D motion management methods: Kilovoltage Intra-fraction Motion management (KIM) and MV/kV triangulation. A planning study assessing the impact of a defined prostate motion (2-5 mm) on the PTV  coverage with and without IMR was performed. A clinically relevant IMR search region for prostate cancer SBRT treatments was determined using a customised anthropomorphic pelvis phantom with implanted gold seeds and a motion platform. IMR showed submillimeter agreement with corresponding 2D projections from both KIM and MV/kV triangulation. However, IMR detected actual displacements consistently in considerably fewer frames than KIM (3D), with the actual numbers depending on the settings. The Default Search Region (DSR) method employing a circular search region proved superior to user-contoured structures in detecting clinically relevant prostate motion. Reducing the DSR search region radius can reduce the impact of the 2D nature of IMR and improve the detectability of actual motion (by 10% per 0.5 mm reduction) but must be balanced against increased beam interruptions from minor, clinically irrelevant motion. The use of IMR for SBRT prostate treatments has the potential to improve target dose coverage (minimum dose to 98% of the PTV, D98%) by > 20% compared to treatment without IMR. Calculated D98% of IMR monitored treatments with motion was within 1.5% of plans without motion.

Markerless motion tracking with simultaneous MV and kV imaging in spine SBRT treatment-a feasibility study

Objective. Motion tracking with simultaneous MV-kV imaging has distinct advantages over single kV systems. This research is a feasibility study of utilizing this technique for spine stereotactic body radiotherapy (SBRT) through phantom and patient studies.Approach. A clinical spine SBRT plan was developed using 6xFFF beams and nine sliding-window IMRT fields. The plan was delivered to a chest phantom on a linear accelerator. Simultaneous MV-kV image pairs were acquired during beam delivery. KV images were triggered at predefined intervals, and synthetic MV images showing enlarged MLC apertures were created by combining multiple raw MV frames with corrections for scattering and intensity variation. Digitally reconstructed radiograph (DRR) templates were generated using high-resolution CBCT reconstructions (isotropic voxel size (0.243 mm)3) as the reference for 2D-2D matching. 3D shifts were calculated from triangulation of kV-to-DRR and MV-to-DRR registrations. To evaluate tracking accuracy, detected shifts were compared to known phantom shifts as introduced before treatment. The patient study included a T-spine patient and an L-spine patient. Patient datasets were retrospectively analyzed to demonstrate the performance in clinical settings.Main results. The treatment plan was delivered to the phantom in five scenarios: no shift, 2 mm shift in one of the longitudinal, lateral and vertical directions, and 2 mm shift in all the three directions. The calculated 3D shifts agreed well with the actual couch shifts, and overall, the uncertainty of 3D detection is estimated to be 0.3 mm. The patient study revealed that with clinical patient image quality, the calculated 3D motion agreed with the post-treatment cone beam CT. It is feasible to automate both kV-to-DRR and MV-to-DRR registrations using a mutual information-based method, and the difference from manual registration is generally less than 0.3 mm.Significance. The MV-kV imaging-based markerless motion tracking technique was validated through a feasibility study. It is a step forward toward effective motion tracking and accurate delivery for spinal SBRT.

The dosimetric error due to uncorrected tumor rotation during real-time adaptive prostate stereotactic body radiation therapy

BACKGROUND

During prostate stereotactic body radiation therapy (SBRT), prostate tumor translational motion may deteriorate the planned dose distribution. Most of the major advances in motion management to date have focused on correcting this one aspect of the tumor motion, translation. However, large prostate rotation up to 30° has been measured. As the technological innovation evolves toward delivering increasingly precise radiotherapy, it is important to quantify the clinical benefit of translational and rotational motion correction over translational motion correction alone.

PURPOSE

The purpose of this work was to quantify the dosimetric impact of intrafractional dynamic rotation of the prostate measured with a six degrees-of-freedom tumor motion monitoring technology.

METHODS

The delivered dose was reconstructed including (a) translational and rotational motion and (b) only translational motion of the tumor for 32 prostate cancer patients recruited on a 5-fraction prostate SBRT clinical trial. Patients on the trial received 7.25 Gy in a treatment fraction. A 5 mm clinical target volume (CTV) to planning target volume (PTV) margin was applied in all directions except the posterior direction where a 3 mm expansion was used. Prostate intrafractional translational motion was managed using a gating strategy, and any translation above the gating threshold was corrected by applying an equivalent couch shift. The residual translational motion is denoted as T r e s $T_{res}$ . Prostate intrafractional rotational motion R u n c o r r $R_{uncorr}$ was recorded but not corrected. The dose differences from the planned dose due to T r e s $T_{res}$ + R u n c o r r $R_{uncorr}$ , ΔD( T r e s $T_{res}$ + R u n c o r r $R_{uncorr}$ ) and due to T r e s $T_{res}$ alone, ΔD( T r e s $T_{res}$ ), were then determined for CTV D98, PTV D95, bladder V6Gy, and rectum V6Gy. The residual dose error due to uncorrected rotation, R u n c o r r $R_{uncorr}$ was then quantified: Δ D R e s i d u a l $\Delta D_{Residual}$ = ΔD( T r e s $T_{res}$ + R u n c o r r $R_{uncorr}$ ) - ΔD( T res ${T}_{\textit{res}}$ ).

RESULTS

Fractional data analysis shows that the dose differences from the plan (both ΔD( T r e s $T_{res}$ + R u n c o r r $R_{uncorr}$ ) and ΔD( T r e s $T_{res}$ )) for CTV D98 was less than 5% in all treatment fractions. ΔD( T r e s $T_{res}$ + R u n c o r r $R_{uncorr}$ ) was larger than 5% in one fraction for PTV D95, in one fraction for bladder V6Gy, and in five fractions for rectum V6Gy. Uncorrected rotation, R u n c o r r $R_{uncorr}$ induced residual dose error, Δ D R e s i d u a l $\Delta D_{Residual}$ , resulted in less dose to CTV and PTV in 43% and 59% treatment fractions, respectively, and more dose to bladder and rectum in 51% and 53% treatment fractions, respectively. The cumulative dose over five fractions, ∑D( T r e s $T_{res}$ + R u n c o r r $R_{uncorr}$ ) and ∑D( T r e s $T_{res}$ ), was always within 5% of the planned dose for all four structures for every patient.

CONCLUSIONS

The dosimetric impact of tumor rotation on a large prostate cancer patient cohort was quantified in this study. These results suggest that the standard 3-5 mm CTV-PTV margin was sufficient to account for the intrafraction prostate rotation observed for this cohort of patients, provided an appropriate gating threshold was applied to correct for translational motion. Residual dose errors due to uncorrected prostate rotation were small in magnitude, which may be corrected using different treatment adaptation strategies to further improve the dosimetric accuracy.

Intrafractional accuracy and efficiency of a surface imaging system for deep inspiration breath hold during ablative gastrointestinal cancer treatment

PURPOSE

Beam gating with deep inspiration breath hold (DIBH) usually depends on some external surrogate to infer internal target movement, and the exact internal movement is unknown. In this study, we tracked internal targets and characterized residual motion during DIBH treatment, guided by a surface imaging system, for gastrointestinal cancer. We also report statistics on treatment time.

METHODS AND MATERIALS

We included 14 gastrointestinal cancer patients treated with surface imaging-guided DIBH volumetrically modulated arc therapy, each with at least one radiopaque marker implanted near or within the target. They were treated in 25, 15, or 10 fractions. Thirteen patients received treatment for pancreatic cancer, and one underwent separate treatments for two liver metastases. The surface imaging system monitored a three-dimensional surface with ± 3 mm translation and ± 3° rotation threshold. During delivery, a kilovolt image was automatically taken every 20° or 40° gantry rotation, and the internal marker was identified from the image. The displacement and residual motion of the markers were calculated. To analyze the treatment efficiency, the treatment time of each fraction was obtained from the imaging and treatment timestamps in the record and verify system.

RESULTS

Although the external surface was monitored and limited to ± 3 mm and ± 3°, significant residual internal target movement was observed in some patients. The range of residual motion was 3-21 mm. The average displacement for this cohort was 0-3 mm. In 19% of the analyzed images, the magnitude of the instantaneous displacement was > 5 mm. The mean treatment time was 17 min with a standard deviation of 4 min.

CONCLUSIONS

Precaution is needed when applying surface image guidance for gastrointestinal cancer treatment. Using it as a solo DIBH technique is discouraged when the correlation between internal anatomy and patient surface is limited. Real-time radiographic verification is critical for safe treatments.

Retrospective analysis of MV-kV imaging-based fiducial tracking in prostate SBRT treatment

PURPOSE

Motion management is critical for prostate stereotactic body radiotherapy (SBRT) due to its high fractional dose and proximity to organs at risk. This study seeks to quantify the advantages of MV-kV tracking over kV imaging alone through a retrospective analysis of over 300 patients who underwent prostate SBRT treatment using MV-kV tracking.

METHODS

An MV-kV imaging-based fiducial tracking technique has been developed at our institute and become a standard clinical practice. This technique calculates three-dimensional (3D) fiducial displacement in real time from orthogonal kV and MV images acquired simultaneously. The patient will be repositioned if for two consecutive MV-kV data points, the motion is larger than a tolerance of 1.5 mm in any of the lateral, superior-inferior, and/or anterior-posterior directions. This study retrospectively analyzed detected 3D motions using an MV-kV approach of 324 patients who recently underwent prostate SBRT treatments. An algorithm was developed to recover the 2D motion components as if they were detected by kV or MV imaging alone.

RESULTS

Our results indicated that out-of-tolerance motions were primarily limited to the range of 1.5-3 mm (>95%). The motions are primarily anterior-posterior and superior-inferior, with less than 14.8% of the occurrences in the lateral direction. Compared to out-of-tolerance occurrences detected by MV-kV approach, kV alone caught 46.6% of motions in all three directions, and MV alone caught 46.7%. kV alone shows an overall missing rate of 45.8% for superior-inferior motions and 38.6% for lateral motions. It is also demonstrated that the detectability of motion in specific directions greatly depends on gantry angles, as does the missing rate.

CONCLUSIONS

Our study demonstrated that MV-kV imaging-based intrafraction motion tracking is superior to single kV imaging for prostate SBRT in clinical practice.

Evaluation of a proprietary software application for motion monitoring during stereotactic paraspinal treatment

PURPOSE

Stereotactic paraspinal treatment has become increasingly popular due to its favorable clinical outcome. An often-overlooked factor that compromises the effectiveness of such treatment is the patients' involuntary intrafractional motion. This work introduces and validates a proprietary software application that quantifies such motion for accurate patient monitoring during treatment.

METHODS

The software uses a separate full-trajectory cone-beam computed tomography (CBCT) after daily patient setup to establish reference projections. Once treatment starts, the software grabs the intrafraction motion review (IMR) image acquired by TrueBeam via the Varian iTools Capture software and compares it against the corresponding reference projection to instantly determine the 2D shifts of the vertebrae being monitored using the classical downhill simplex optimization method. To evaluate its performance, an anthropomorphic phantom was shifted 0, 0.6, 1.2, 1.8, 2.4, 3.0, and 5 mm in three orthogonal directions, immediately after the full-trajectory CBCT but prior to treatment. Depending on the scenario of shift, a nine-field fixed gantry intensity-modulated radiation therapy (IMRT) plan and/or a four partial-posterior-arcs volume-modulated radiation therapy (VMAT) plan were delivered. For the IMRT plan, three IMR images were acquired sequentially every 200 monitor units (MU) at each treatment angle. For the VMAT plan, one IMR image was acquired every 15° of each arc. For each IMR image, the software-reported 2D shift was compared with the ground truth. Certain tests were repeated with 1°, 2°, and 3° of rotation, pitch, and roll, respectively. Some of these tests were also repeated independently on separate days.

RESULTS

Based on the group of tests that involved only the IMRT delivery, the maximum standard deviation of the software-reported shifts for each set of three IMR images was 0.16 mm, with 95th percentile at 0.02 mm. For translational shift, the maximum registration error was 0.44 mm, with 95th percentile at 0.23 mm. Left unaccounted for, rotation and pitch degraded the registration accuracy mainly in the longitudinal direction, while roll degraded it mainly in the lateral direction. The degradation of registration accuracy is positively related to the degree of rotation, pitch, and roll. The maximum registration errors under 3° rotation, pitch, and roll were 2.97, 1.44, 2.72 mm, respectively. Based on the group of tests that compared IMRT delivery with VMAT delivery, the registration errors slightly increased as magnitude of shifts increased; however, they were well under the 0.5-mm threshold. No significant differences in registration errors were observed between IMRT and VMAT deliveries. In addition, the variation in registration errors among different days was limited for both IMRT and VMAT deliveries.

CONCLUSIONS

Our proprietary software has high repeatability, both intrafractionally and interfractionally, and high accuracy in registering IMR images with the reference projections for motion monitoring, regardless of the magnitude of shifts or treatment delivery technique. Rotation, pitch, and roll degrade registration accuracy and need to be accounted for in the future work.

Comprehensive characterization of ExacTrac stereoscopic image guidance system using Monte Carlo and Spektr simulations

The purpose of this work is to develop accurate computational methods to comprehensively characterize and model the clinical ExacTrac imaging system, which is used as an image guidance system for stereotactic treatment applications. The Spektr toolkit was utilized to simulate the spectral and imaging characterization of the system. Since Spektr only simulates the primary beam (ignoring scatter), a full model of ExacTrac was also developed in Monte Carlo (MC) to characterize the imaging system. To ensure proper performance of both simulation models, Spektr and MC data were compared to the measured spectral and half value layers (HVLs) values. To validate the simulation results, x-ray spectra of the ExacTrac system were measured for various tube potentials using a CdTe spectrometer with multiple added narrow collimators. The raw spectra were calibrated using a ⁵⁷Co source and corrected for the escape peaks and detector efficiency. HVLs in mm of Al for various energies were measured using a calibrated RaySafe detector. Spektr and MC HVLs were calculated and compared to the measured values. The patient surface dose was calculated for different clinical imaging protocols from the measured air kerma and HVL values following the TG-61 methodology. The x-ray focal spot was measured by slanted edge technique using gafchromic films. ExacTrac imaging system beam profiles were simulated for various energies by MC simulation and the results were benchmarked by experimentally acquired beam profiles using gafchromic films. The effect of 6D IGRT treatment couch on beam hardening, dynamic range of the flat panel detector and scatter effect were determined using both Spektr simulation and experimental measurements. The measured and simulated spectra (of both MC and Spektr) for various kVps were compared and agreed within acceptable error. As another validation, the measured HVLs agreed with the Spektr and MC simulated HVLs on average within 1.0% for all kVps. The maximum and minimum patient surface doses were found to be 1.06 mGy for shoulder (high) and 0.051 mGy for cranial (low) imaging protocols, respectively. The MC simulated beam profiles were well matched with experimental results and replicated the penumbral slopes, the heel effect, and out-of-field regions. Dynamic range of detector (in terms of air kerma at detector surface) was found to be in the range of [6.1 × 10^-6, 5.3 × 10^-3] mGy. Accurate MC and Spektr models of the ExacTrac image guidance system were successfully developed and benchmarked via experimental validation. While patient surface dose for available imaging protocols were reported in this study, the established MC model may be used to obtain 3D imaging dose distribution for real patient geometries.

Quantification and correction of the scattered X-rays from a megavoltage photon beam to a linac-mounted kilovoltage imaging subsystem

Objective

To quantify and correct megavoltage (MV) scattered X-rays (MV-scatter) on an image acquired using a linac-mounted kilovoltage (kV) imaging subsystem.

Methods and materials

A linac-mounted flat-panel detector (FPD) was used to acquire an image containing MV-scatter by activating the FPD only during MV beam irradiation. 6-, 10-, and 15 MV with a flattening-filter (FF; 6X-FF, 10X-FF, 15X-FF), and 6- and 10 MV without an FF (6X-FFF, 10X-FFF) were used. The maps were acquired by changing one of the irradiation parameters while the others remained fixed. The mean pixel values of the MV-scatter were normalized to the 6X-FF reference condition (MV-scatter value). An MV-scatter database was constructed using these values. An MV-scatter correction experiment with one full arc image acquisition and two square field sizes (FSs) was conducted. Measurement- and estimation-based corrections were performed using the database. The image contrast was calculated at each angle.

Results

The MV-scatter increased with a larger FS and dose rate. The MV-scatter value factor varied substantially depending on the FPD position or collimator rotation. The median relative error ranges of the contrast for the image without, and with the measurement- and estimation-based correction were -10.9 to -2.9, and -1.5 to 4.8 and -7.4 to 2.6, respectively, for an FS of 10.0 × 10.0 cm².

Conclusions

The MV-scatter was strongly dependent on the FS, dose rate, and FPD position. The MV-scatter correction improved the image contrast.

Advances in knowledge

The MV-scatters on the TrueBeam linac kV imaging subsystem were quantified with various MV beam parameters, and strongly depended on the fieldsize, dose rate, and flat panel detector position. The MV-scatter correction using the constructed database improved the image quality.

Technical Note: Synthetic treatment beam imaging for motion monitoring during spine SBRT treatments - a phantom study

PURPOSE

One of the biggest challenges in applying megavoltage (MV) treatment beam imaging for monitoring spine motion in stereotactic body radiotherapy (SBRT) is the small beam apertures in the images due to strong beam modulations in IMRT planning. The purpose of this study is to investigate the feasibility of a markerless motion tracking method in spine SBRT delivery using a novel enhanced synthetic treatment beam (ESTB) imaging technique.

METHODS

Three clinical spine SBRT plans using 6XFFF beams and sliding window IMRT technique were transferred to a thorax phantom and delivered by a TrueBeam machine. Before delivery, the phantom was aligned to the plan isocenter using CBCT setup and verified with a second CBCT, and then, 2 mm shifts were introduced in both the craniocaudal (CC) and the left-right (LR) directions with the couch. During beam delivery, MV images were continuously taken with an electronic portal imaging device (EPID) and automatically grabbed by Varian iTools Capture software with a frame rate of 11.6 Hz. After preprocessing for scatter correction and beam intensity compensation, every 50 frames of MV images were combined to generate a series of ESTB images for each beam. The ESTB images were then registered to the projections of the verification CBCT at the matched beam angles to detect the 2 mm shifts.

RESULTS

Compared to snapshot MV images, the ESTB images had significantly enlarged fields of view (FOVs) and improved image quality. Based on two-dimensional (2D) rigid registration, the ESTB image to CBCT projection matching showed submillimeter accuracy in detecting motion. Specifically, the root mean square errors in detecting the LR/CC shifts were 0.35/0.28, 0.32/0.35, 0.63/0.44, 0.55/0.51, and 0.69/0.42 mm at gantry angles 180, 160, 140, 120, and 100, respectively.

CONCLUSION

Our results in the phantom study suggest that ESTB images from a sliding window IMRT plan can be used to detect spine motion, with submillimeter precision in the 2D plane perpendicular to the beam.

Couch and multileaf collimator tracking: A clinical feasibility study for pancreas and liver treatment

PURPOSE

Real-time tumor tracking through active correction by the multileaf collimator or treatment couch offers a promising strategy to mitigate delivery uncertainty due to intrafractional tumor motion. This study evaluated the performance of MLC and couch tracking using the prototype iTools Tracking system in TrueBeam Developer Mode and the application for abdominal cancer treatments.

METHODS

Experiments were carried out using a phantom with embedded Calypso transponders and a motion simulation platform. Geometric evaluations were performed using a circular conformal field with sinusoidal traces and pancreatic tumor motion traces. Geometric tracking accuracy was retrospectively calculated by comparing the compensational MLC or couch motion extracted from machine log files to the target motion reconstructed from real-time MV and kV images. Dosimetric tracking accuracy was measured with radiochromic films using clinical abdominal VMAT plans and pancreatic tumor traces.

RESULTS

Geometrically, the root-mean-square errors for MLC tracking were 0.5 and 1.8 mm parallel and perpendicular to leaf travel direction, respectively. Couch tracking, in contrast, showed an average of 0.8 mm or less geometric error in all directions. Dosimetrically, both MLC and couch tracking reduced motion-induced local dose errors compared to no tracking. Evaluated with five pancreatic tumor motion traces, the average 2%/2 mm global gamma pass rate of eight clinical abdominal VMAT plans was 67.4% (range: 26.4%-92.7%) without tracking, which was improved to 86.0% (range: 67.9%-95.6%) with MLC tracking, and 98.1% (range: 94.9%-100.0%) with couch tracking. In 16 out of 40 deliveries with different plans and motion traces, MLC tracking did not achieve clinically acceptable dosimetric accuracy with 3%/3mm gamma pass rate below 95%.

CONCLUSIONS

This study demonstrated the capability of MLC and couch tracking to reduce motion-induced dose errors in abdominal cases using a prototype tracking system. Clinically significant dose errors were observed with MLC tracking for certain plans which could be attributed to the inferior MLC tracking accuracy in the direction perpendicular to leaf travel, as well as the interplay between motion tracking and plan delivery for highly modulated plans. Couch tracking outperformed MLC tracking with consistently high dosimetric accuracy in all plans evaluated, indicating its clinical potential in the treatment of abdominal cancers.

Prostate SBRT With Intrafraction Motion Management Using a Novel Linear Accelerator-Based MV-kV Imaging Method

PURPOSE

This study reports clinical experience using a linear accelerator-based MV-kV imaging system for intrafraction motion management during prostate stereotactic body radiation therapy (SBRT).

METHODS AND MATERIALS

From June 2016 to August 2018, 193 prostate SBRT patients were treated using MV-kV motion management (median dose 40 Gy in 5 fractions). Patients had 3 fiducials implanted then simulated and treated with a full bladder and empty rectum. Pretreatment orthogonal kVs and cone beam computed tomography were used to position patients and evaluate internal anatomy. Motion was tracked during volumetric modulated arc therapy delivery using simultaneously acquired kV and MV images from standard on-board systems. Treatment was interrupted to reposition patients when motion >1.5-2 mm was detected. Motion traces were analyzed and compared with Calypso traces from a previously treated similar patient cohort. To evaluate "natural motion" (ie, if we had not interrupted treatment and repositioned), intrafraction couch corrections were removed from all traces. Clinical effectiveness of the MV-kV system was explored by evaluating toxicity (Common Terminology Criteria for Adverse Events v3.0) and biochemical recurrence rates (nadir + 2 ng/mL).

RESULTS

Median number of interruptions for patient repositioning was 1 per fraction (range, 0-9). Median overall treatment time was 8.2 minutes (range, 4.2-44.8 minutes). Predominant motion was inferior and posterior, and probability of motion increased with time. Natural motion >3 mm and >5 mm in any direction was observed in 32.3% and 10.2% of fractions, respectively. Calypso monitoring (n = 50) demonstrated similar motion results. In the 151 MV-kV patients with ≥3-month follow-up (median, 9.5 months; range, 3-26.5 months), grade ≥2 acute genitourinary/gastrointestinal and late genitourinary/gastrointestinal toxicity was observed in 9.9%/2.0% and 11.9%/2.7%, respectively. Biochemical control was 99.3% with a single failure in a high-risk patient.

CONCLUSIONS

The MV-kV system is an effective method to manage intrafraction prostate motion during SBRT, offering the opportunity to correct for prostate clinical target volume displacements that would have otherwise extended beyond typical planning target volume margins.

Technical Note: 3D localization of lung tumors on cone beam CT projections via a convolutional recurrent neural network

PURPOSE

To design a convolutional recurrent neural network (CRNN) that calculates three-dimensional (3D) positions of lung tumors from continuously acquired cone beam computed tomography (CBCT) projections, and facilitates the sorting and reconstruction of 4D-CBCT images.

METHOD

Under an IRB-approved clinical lung protocol, kilovoltage (kV) projections of the setup CBCT were collected in free-breathing. Concurrently, an electromagnetic signal-guided system recorded motion traces of three transponders implanted in or near the tumor. Convolutional recurrent neural network was designed to utilize a convolutional neural network (CNN) for extracting relevant features of the kV projections around the tumor, followed by a recurrent neural network for analyzing the temporal patterns of the moving features. Convolutional recurrent neural network was trained on the simultaneously collected kV projections and motion traces, subsequently utilized to calculate motion traces solely based on the continuous feed of kV projections. To enhance performance, CRNN was also facilitated by frequent calibrations (e.g., at 10° gantry rotation intervals) derived from cross-correlation-based registrations between kV projections and templates created from the planning 4DCT. Convolutional recurrent neural network was validated on a leave-one-out strategy using data from 11 lung patients, including 5500 kV images. The root-mean-square error between the CRNN and motion traces was calculated to evaluate the localization accuracy.

RESULT

Three-dimensional displacement around the simulation position shown in the Calypso traces was 3.4 ± 1.7 mm. Using motion traces as ground truth, the 3D localization error of CRNN with calibrations was 1.3 ± 1.4 mm. CRNN had a success rate of 86 ± 8% in determining whether the motion was within a 3D displacement window of 2 mm. The latency was 20 ms when CRNN ran on a high-performance computer cluster.

CONCLUSIONS

CRNN is able to provide accurate localization of lung tumors with aid from frequent recalibrations using the conventional cross-correlation-based registration approach, and has the potential to remove reliance on the implanted fiducials.

Early Tolerance and Tumor Control Outcomes with High-dose Ultrahypofractionated Radiation Therapy for Prostate Cancer

BACKGROUND

Studies using stereotactic body radiotherapy (SBRT) dose escalation in in low- and intermediate-risk prostate cancer patients have indicated favorable outcomes.

OBJECTIVE

To evaluate tolerance and tumor control outcomes in low- and intermediate-risk prostate cancer patients treated with high-dose SBRT following our phase 1 trial.

DESIGN, SETTING, AND PARTICIPANTS

A total of 551 patients with low- or intermediate-risk prostate cancer were treated with SBRT.

INTERVENTION

Treatment with 37.5-40Gy SBRT in five fractions directed to the prostate and seminal vesicles.

OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS

Outcome measurements included acute toxicities (<3 mo after radiotherapy [RT]) and late toxicities (>3 mo after RT) and tumor control evaluation (prostate-specific antigen [PSA] levels at 3-6-mo intervals and post-treatment prostate biopsy at 2yr).

RESULTS AND LIMITATIONS

Acute grade 2 gastrointestinal (GI) toxicities occurred in 1.8% of patients, and late grade 2 and 3 GI toxicities were observed in 3.4% and 0.4% of patients, respectively. Acute grade 2 genitourinary (GU) toxicities occurred in 10% of patients, and grade 3 acute GU toxicities were observed in 0.7% of patients. Late grade 2 and 3 GU toxicities were observed in 21.1% and 2.5% of patients, respectively. The use of a hydrogel rectal spacer was significantly associated with reduced late GI toxicity and lower odds of developing late GU toxicity. The median follow-up was 17 mo, and 53% of those with at least 2yr of follow-up (103/193) had a biopsy performed. The 5-yr cumulative incidence of PSA failure was 2.1%, and the incidence of a positive 2-yr treatment biopsy was 12%. Limitations to this report include its retrospective nature and short follow-up time.

CONCLUSIONS

Favorable short-term outcomes were achieved with high-dose SBRT for low- and intermediate-risk disease. Severe late toxicities were observed and favorable tumor control was found.

PATIENT SUMMARY

We utilized stereotactic body radiotherapy, a form of external beam radiotherapy that delivers highly targeted high-dose treatment to the prostate, to treat over 500 localized prostate cancer patients in five sessions over 1.5 wk. Treatments were well tolerated without significant urinary or rectal side effects. Nearly 90% of those who underwent biopsies after treatment did not demonstrate residual active disease.

Real-time intrafraction motion monitoring in external beam radiotherapy

Radiotherapy (RT) aims to deliver a spatially conformal dose of radiation to tumours while maximizing the dose sparing to healthy tissues. However, the internal patient anatomy is constantly moving due to respiratory, cardiac, gastrointestinal and urinary activity. The long term goal of the RT community to 'see what we treat, as we treat' and to act on this information instantaneously has resulted in rapid technological innovation. Specialized treatment machines, such as robotic or gimbal-steered linear accelerators (linac) with in-room imaging suites, have been developed specifically for real-time treatment adaptation. Additional equipment, such as stereoscopic kilovoltage (kV) imaging, ultrasound transducers and electromagnetic transponders, has been developed for intrafraction motion monitoring on conventional linacs. Magnetic resonance imaging (MRI) has been integrated with cobalt treatment units and more recently with linacs. In addition to hardware innovation, software development has played a substantial role in the development of motion monitoring methods based on respiratory motion surrogates and planar kV or Megavoltage (MV) imaging that is available on standard equipped linacs. In this paper, we review and compare the different intrafraction motion monitoring methods proposed in the literature and demonstrated in real-time on clinical data as well as their possible future developments. We then discuss general considerations on validation and quality assurance for clinical implementation. Besides photon RT, particle therapy is increasingly used to treat moving targets. However, transferring motion monitoring technologies from linacs to particle beam lines presents substantial challenges. Lessons learned from the implementation of real-time intrafraction monitoring for photon RT will be used as a basis to discuss the implementation of these methods for particle RT.

Adaptive Imaging Versus Periodic Surveillance for Intrafraction Motion Management During Prostate Cancer Radiotherapy

Objective:

To evaluate the benefits of adaptive imaging with automatic correction compared to periodic surveillance strategies with either manual or automatic correction.

Methods:

Using Calypso trajectories from 54 patients with prostate cancer at 2 institutions, we simulated 5-field intensity-modulated radiation therapy and dual-arc volumetric-modulated arc therapy with periodic imaging at various frequencies and with continuous adaptive imaging, respectively. With manual/automatic correction, we assumed there was a 30/1 second delay after imaging to determine and apply couch shift. For adaptive imaging, real-time “dose-free” cine-MV images during beam delivery are used in conjunction with online-updated motion pattern information to estimate 3D displacement. Simultaneous MV-kV imaging is only used to confirm the estimated overthreshold motion and calculate couch shift, hence very low additional patient dose from kV imaging.

Results:

Without intrafraction intervention, the prostates could on average have moved out of a 3-mm margin for ∼20% of the beam-on time after setup imaging in current clinical situation. If the time interval from the setup imaging to beam-on can be reduced to only 30 seconds, the mean over-3 mm percentage can be reduced to ∼7%. For intensity-modulated radiation therapy simulation, with manual correction, 110 and 70 seconds imaging periods both reduced the mean over-3 mm time to ∼4%. Automatic correction could give another 1% to 2% improvement. However, with either manual or automatic correction, the maximum patient-specific over-3 mm time was still relatively high (from 6.4% to 12.6%) and those patients are actually clinically most important. In contrast, adaptive imaging with automatic intervention significantly reduced the mean percentage to 0.6% and the maximum to 2.7% and averagely only ∼1 kV image and ∼1 couch shift were needed per fraction. The results of volumetric-modulated arc therapy simulation show a similar trend to that of intensity-modulated radiation therapy.

Conclusions:

Adaptive continuous monitoring with automatic motion compensation is more beneficial than periodic imaging surveillance at similar or even less imaging dose.

Developing a MLC modifier program to improve fiducial detection for MV/kV imaging during hypofractionated prostate volumetric modulated arc therapy

Purpose

To develop an Eclipse plug‐in (MLC_MODIFIER) that automatically modifies control points to expose fiducials obscured by MLC during VMAT, thereby facilitating tracking using periodic MV/kV imaging.

Method

Three‐dimensional fiducial tracking was performed during VMAT by pairing short‐arc (3°) MV digital tomosynthesis (DTS) images to triggered kV images. To evaluate MLC_MODIFIER efficacy, two cohorts of patients were considered. For first 12 patients, plans were manually edited to expose one fiducial marker. Next for 15 patients, plans were modified using MLC_MODIFIER script. MLC_MODIFIER evaluated MLC apertures at appropriate angles for marker visibility. Angles subtended by control points were compressed and low‐dose “imaging” control points were inserted and exposed one marker with 1 cm margin. Patient's images were retrospectively reviewed to determine rate of MV registration failures. Failure categories were poor DTS image quality, MLC blockage of fiducials, or unknown reasons. Dosimetric differences in rectum, bladder, and urethra D1 cc, PTV maximum dose, and PTV dose homogeneity (PTV HI) were evaluated. Statistical significance was evaluated using Fisher's exact and Student's t test.

Result

Overall MV registration failures, failures due to poor image quality, MLC blockage, and unknown reasons were 33% versus 8.9% (P < 0.0001), 8% versus 6.4% (P < 0.05), 13.6% versus 0.1% (P < 0.0001), and 7.6% versus 2.4% (P < 0.0001) for manually edited and MLC_MODIFIER plans, respectively. PTV maximum and HI increased on average from unmodified plans by 2.1% and 0.3% (P < 0.004) and 22.0% and 3.3% (P < 0.004) for manually edited and MLC_MODIFIED plans, respectively. Changes in bladder, rectum, and urethra D1CC were similar for each method and less than 0.7%.

Conclusion

Increasing fiducial visibility via an automated process comprised of angular compression of control points and insertion of additional “imaging” control points is feasible. Degradation of plan quality is minimal. Fiducial detection and registration success rates are significantly improved compared to manually edited apertures.

Review of Real-Time 3-Dimensional Image Guided Radiation Therapy on Standard-Equipped Cancer Radiation Therapy Systems: Are We at the Tipping Point for the Era of Real-Time Radiation Therapy?

PURPOSE

To review real-time 3-dimensional (3D) image guided radiation therapy (IGRT) on standard-equipped cancer radiation therapy systems, focusing on clinically implemented solutions.

METHODS AND MATERIALS

Three groups in 3 continents have clinically implemented novel real-time 3D IGRT solutions on standard-equipped linear accelerators. These technologies encompass kilovoltage, combined megavoltage-kilovoltage, and combined kilovoltage-optical imaging. The cancer sites treated span pelvic and abdominal tumors for which respiratory motion is present. For each method the 3D-measured motion during treatment is reported. After treatment, dose reconstruction was used to assess the treatment quality in the presence of motion with and without real-time 3D IGRT. The geometric accuracy was quantified through phantom experiments. A literature search was conducted to identify additional real-time 3D IGRT methods that could be clinically implemented in the near future.

RESULTS

The real-time 3D IGRT methods were successfully clinically implemented and have been used to treat more than 200 patients. Systematic target position shifts were observed using all 3 methods. Dose reconstruction demonstrated that the delivered dose is closer to the planned dose with real-time 3D IGRT than without real-time 3D IGRT. In addition, compromised target dose coverage and variable normal tissue doses were found without real-time 3D IGRT. The geometric accuracy results with real-time 3D IGRT had a mean error of <0.5 mm and a standard deviation of <1.1 mm. Numerous additional articles exist that describe real-time 3D IGRT methods using standard-equipped radiation therapy systems that could also be clinically implemented.

CONCLUSIONS

Multiple clinical implementations of real-time 3D IGRT on standard-equipped cancer radiation therapy systems have been demonstrated. Many more approaches that could be implemented were identified. These solutions provide a pathway for the broader adoption of methods to make radiation therapy more accurate, impacting tumor and normal tissue dose, margins, and ultimately patient outcomes.

Design and validation of a MV/kV imaging-based markerless tracking system for assessing real-time lung tumor motion

PURPOSE

Localizing lung tumors during treatment delivery is critical for managing respiratory motion, ensuring tumor coverage, and reducing toxicities. The purpose of this project is to develop a real-time system that performs markerless tracking of lung tumors using simultaneously acquired MV and kV images during radiotherapy of lung cancer with volumetric modulated arc therapy.

METHOD

Continuous MV/kV images were simultaneously acquired during dose delivery. In the subsequent analysis, a gantry angle-specific region of interest was defined according to the treatment aperture. After removing imaging artifacts, processed MV/kV images were directly registered to the corresponding daily setup cone-beam CT (CBCT) projections that served as reference images. The registration objective function consisted of a sum of normalized cross-correlation, weighted by the contrast-to-noise ratio of each MV and kV image. The calculated 3D shifts of the tumor were corrected by the displacements between the CBCT projections and the planning respiratory correlated CT (RCCT) to generate motion traces referred to a specific respiratory phase. The accuracy of the algorithm was evaluated on both anthropomorphic phantom and patient studies. The phantom consisted of localizing a 3D printed tumor, embedded in a thorax phantom, in an arc delivery. In an IRB-approved study, data were obtained from VMAT treatments of two lung cancer patients with three electromagnetic (Calypso) beacon transponders implanted in airways near the lung tumor.

RESULT

In the phantom study, the root mean square error (RMSE) between the registered and actual (programmed couch movement) target position was 1.2 mm measured by the MV/kV imaging system, which was smaller compared to the MV or kV alone, of 4.1 and 1.3 mm, respectively. In the patient study, the mean and standard deviation discrepancy between electromagnetic-based tumor position and the MV/KV-markerless approach was -0.2 ± 0.6 mm, 0.2 ± 1.0 mm, and -1.2 ± 1.5 mm along the superior-inferior, anterior-posterior, and left-right directions, respectively; resulting in a 3D displacement discrepancy of 2.0 ± 1.1 mm. Poor contrast around the tumor was the main contribution to registration uncertainties.

CONCLUSION

The combined MV/kV imaging system can provide real-time 3D localization of lung tumor, with comparable accuracy to the electromagnetic-based system when features of tumors are detectable. Careful design of a registration algorithm and a VMAT plan that maximizes the tumor visibility are key elements for a successful MV/KV localization strategy.

Evaluation of 2D and 3D ultrasound tracking algorithms and impact on ultrasound-guided liver radiotherapy margins

PURPOSE

Compensation for respiratory motion is important during abdominal cancer treatments. In this work we report the results of the 2015 MICCAI Challenge on Liver Ultrasound Tracking and extend the 2D results to relate them to clinical relevance in form of reducing treatment margins and hence sparing healthy tissues, while maintaining full duty cycle.

METHODS

We describe methodologies for estimating and temporally predicting respiratory liver motion from continuous ultrasound imaging, used during ultrasound-guided radiation therapy. Furthermore, we investigated the trade-off between tracking accuracy and runtime in combination with temporal prediction strategies and their impact on treatment margins.

RESULTS

Based on 2D ultrasound sequences from 39 volunteers, a mean tracking accuracy of 0.9 mm was achieved when combining the results from the 4 challenge submissions (1.2 to 3.3 mm). The two submissions for the 3D sequences from 14 volunteers provided mean accuracies of 1.7 and 1.8 mm. In combination with temporal prediction, using the faster (41 vs 228 ms) but less accurate (1.4 vs 0.9 mm) tracking method resulted in substantially reduced treatment margins (70% vs 39%) in contrast to mid-ventilation margins, as it avoided non-linear temporal prediction by keeping the treatment system latency low (150 vs 400 ms). Acceleration of the best tracking method would improve the margin reduction to 75%.

CONCLUSIONS

Liver motion estimation and prediction during free-breathing from 2D ultrasound images can substantially reduce the in-plane motion uncertainty and hence treatment margins. Employing an accurate tracking method while avoiding non-linear temporal prediction would be favorable. This approach has the potential to shorten treatment time compared to breath-hold and gated approaches, and increase treatment efficiency and safety.

First online real-time evaluation of motion-induced 4D dose errors during radiotherapy delivery

PURPOSE

In radiotherapy, dose deficits caused by tumor motion often far outweigh the discrepancies typically allowed in plan-specific quality assurance (QA). Yet, tumor motion is not usually included in present QA. We here present a novel method for online treatment verification by real-time motion-including four-dimensional (4D) dose reconstruction and dose evaluation and demonstrate its use during stereotactic body radiotherapy (SBRT) delivery with and without MLC tracking.

METHODS

Five volumetric-modulated arc therapy (VMAT) plans were delivered with and without MLC tracking to a motion stage carrying a Delta4 dosimeter. The VMAT plans have previously been used for (nontracking) liver SBRT with intratreatment tumor motion recorded by kilovoltage intrafraction monitoring (KIM). The motion stage reproduced the KIM-measured tumor motions in three dimensions (3D) while optical monitoring guided the MLC tracking. Linac parameters and the target position were streamed to an in-house developed software program (DoseTracker) that performed real-time 4D dose reconstructions and 3%/3 mm γ-evaluations of the reconstructed cumulative dose using a concurrently reconstructed planned dose without target motion as reference. Offline, the real-time reconstructed doses and γ-evaluations were validated against 4D dosimeter measurements performed during the experiments.

RESULTS

In total, 181,120 dose reconstructions and 5,237 γ-evaluations were performed online and in real time with median computation times of 30 ms and 1.2 s, respectively. The mean (standard deviation) difference between reconstructed and measured doses was -1.2% (4.9%) for transient doses and -1.5% (3.9%) for cumulative doses. The root-mean-square deviation between reconstructed and measured motion-induced γ-fail rates was 2.0%-point. The mean (standard deviation) sensitivity and specificity of DoseTracker to predict γ-fail rates above a given threshold was 96.8% (3.5%) and 99.2% (0.4%), respectively, for clinically relevant thresholds between 1% and 30% γ-fail rate.

CONCLUSIONS

Real-time delivery-specific QA during radiotherapy of moving targets was demonstrated for the first time. It allows supervision of treatment accuracy and action on treatment discrepancy within 2 s with high sensitivity and specificity.

Optimizing fiducial visibility on periodically acquired megavoltage and kilovoltage image pairs during prostate volumetric modulated arc therapy

PURPOSE

Robust detection of implanted fiducials is essential for monitoring intrafractional motion during hypofractionated treatment. The authors developed a plan optimization strategy to ensure clear visibility of implanted fiducials and facilitate 3D localization during volumetric modulated arc therapy (VMAT).

METHODS

Periodic kilovoltage (kV) images were acquired at 20° gantry intervals and paired with simultaneously acquired 4.4° short arc megavoltage digital tomosynthesis (MV-DTS) to localize three fiducials during VMAT delivery for hypofractionated prostate cancer treatment. Beginning with the original optimized plan, control point segments where fiducials were consistently blocked by multileaf collimator (MLC) within each 4.4° MV-DTS interval were first identified. For each segment, MLC apertures were edited to expose the fiducial that led to the least increase in the cost function. Subsequently, MLC apertures of all control points not involved with fiducial visualization were reoptimized to compensate for plan quality losses and match the original dose-volume histogram. MV dose for each MV-DTS was also kept above 0.4 MU to ensure acceptable image quality. Different imaging (gantry) intervals and visibility margins around fiducials were also evaluated.

RESULTS

Fiducials were consistently blocked by the MLC for, on average, 36% of the imaging control points for five hypofractionated prostate VMAT plans but properly exposed after reoptimization. Reoptimization resulted in negligible dosimetric differences compared with original plans and outperformed simple aperture editing: on average, PTV D98 recovered from 87% to 94% of prescription, and PTV dose homogeneity improved from 9% to 7%. Without violating plan objectives and compromising delivery efficiency, the highest imaging frequency and largest margin that can be achieved are a 10° gantry interval, and 15 mm, respectively.

CONCLUSIONS

VMAT plans can be made to accommodate MV-kV imaging of fiducials. Fiducial visualization rate and workflow efficiency are significantly improved with an automatic modification and reoptimization approach.